Department of Internal Medicine I, Division of Infectious Diseases, Medical University of Vienna, Vienna, Austria.
Antimicrob Agents Chemother. 2011 Feb;55(2):931-3. doi: 10.1128/AAC.00881-10. Epub 2010 Nov 22.
The activity of fosfomycin was evaluated in an experimental methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis model. Eighteen rats were treated for 4 weeks with 150 mg of fosfomycin/kg of body weight intraperitoneally once daily or with saline placebo. After treatment, animals were euthanized and the infected tibiae were processed for quantitative bacterial culture. Bone cultures were positive for methicillin-resistant S. aureus in all 9 (100%) untreated controls and in 2 of 9 (22.2%) fosfomycin-treated rats. Thus, fosfomycin treatment was significantly more efficacious than placebo. No development of resistance was observed after the 4-week treatment period.
磷霉素的活性在耐甲氧西林金黄色葡萄球菌（MRSA）骨感染模型中进行了评估。18 只大鼠接受了为期 4 周的治疗，每天腹腔内注射 150mg/kg 体重的磷霉素或生理盐水安慰剂。治疗后，动物被安乐死，感染的胫骨进行定量细菌培养。未经治疗的对照组中，有 9 只（100%）和接受磷霉素治疗的大鼠中，有 2 只（22.2%）的骨培养物对耐甲氧西林金黄色葡萄球菌呈阳性。因此，磷霉素治疗明显比安慰剂更有效。在 4 周的治疗期间没有观察到耐药性的发展。
